The global Enzyme Linked Immunosorbent Assay market offers immense opportunities for diagnosis and treatment of various diseases and infections due multiple advantages over other diagnostic tests. ELISA provides high sensitivity and specificity in detection of various antibodies and antigens. It has widespread applications in detecting antibodies and secreted proteins, food and drink analysis and other biological substances.
The Global Enzyme Linked Immunosorbent Assay Market is estimated to be valued at US$ 2441 Mn in 2024 and is expected to exhibit a CAGR of 8.8% over the forecast period from 2024 to 2030.
ELISA is one of the most commonly used medical diagnostic techniques that detects and quantifies various substances such as proteins, antibodies, hormones and toxins in body fluids such as blood, urine or tissue samples. Its widespread adoption is attributed to its high accuracy, sensitivity and reproducibility that makes it an affordable, effective and convenient diagnostic tool across various industries like healthcare, food safety and environmental testing. It offers significant advantages like rapid analysis, automation and can detect low concentrations of antigens and antibodies even when serum is diluted. The technology offers a fast, reliable and quantitative measurement of targeted proteins and antibody levels in serum and plasma samples. The Global Enzyme Linked Immunosorbent Assay Market is driven by rising incidences of chronic and infectious diseases driving the demand for enhanced diagnostics, increasing investments and technological advancements.
Key Takeaways
Key players operating in the Enzyme Linked Immunosorbent Assay are DSV, a.p. moller – maersk, United Parcel Service of America, Inc., XPO Logistics Inc., DHL International GmbH, Kuehne+Nagel Inc., Geodis, FedEx Corporation, C.H. Robinson Worldwide, Inc., db schenker.
The ELISA market is witnessing significant growth owing to rising incidence of chronic diseases, growing aging population and increased demand for early and accurate disease diagnosis. Growing investments for disease diagnostics and technological advancements to develop high throughput automated ELISA kits are further propelling the market growth.
Globally, North America dominates the ELISA market followed by Europe. However, Asia Pacific region is expected to witness highest CAGR over the forecast period driven by rising healthcare spending, increasing disposable incomes, growing middle class population and rapid development of healthcare infrastructure in emerging economies like China & India.
Market key trends
One of the key trends witnessed in the ELISA market is the continuous development of advanced high throughput automated ELISA systems. Automation in ELISA reduces manual errors, saves time and provides accurate quantitative results. Development of enhanced chemiluminescent ELISA technology has led to improved specificity and sensitivity making it convenient and precise diagnostic tool for various clinical applications. Investments for new advanced chemiluminescent high throughput ELISA immunoassay systems is a major trend shaping competitive scenario. Growing adoption of microfluidics-based ELISA systems is another trend leveraging benefits of microfluidic technology like low reagent consumption and rapid analysis of multiple samples. Development of simple, economic paper-based ELISA technology offers potential for low-cost point-of-care applications especially in low resource settings.
Porter’s Analysis
Threat of new entrants: It is moderate as new players require significant investment in R&D to develop new products.
Bargaining power of buyers: It is high as buyers have several alternatives and products are less differentiated.
Bargaining power of suppliers: It is moderate as raw materials are available from multiple suppliers globally.
Threat of new substitutes: The threat is low as ELISA technique competes with other techniques which target different end applications.
Competitive rivalry: It is intense as the market is highly fragmented with presence of several global as well as local players.
Geographical regions:
North America accounts for the largest share of the ELISA market in terms of value owing to presence of major players, dedicated R&D investments, availability of skilled professionals and supportive reimbursement policies. Asia Pacific is emerging as the fastest growing regional market owing to rising prevalence of chronic and infectious diseases, increasing healthcare spending and growing砜investments by market players to tap opportunities in emerging Asian countries.
